Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

• ClinicalTrials.gov Identifier: NCT04209530
• Recruitment Status: Terminated
• First Posted: December 24, 2019
• Results First Posted: October 7, 2021
• Last Update Posted: October 7, 2021
• Sponsor: Endo Pharmaceuticals
• Information provided by (Responsible Party): Endo Pharmaceuticals

Study Description

Brief Summary:

This is a single center, open-label, Phase 2a study to assess the photonumeric scale, morphological, and histopathological changes associated with Collagenase Clostridium Histolyticum (CCH) in adult women with moderate or severe Edematous Fibrosclerotic Panniculopathy (EFP).

Condition or disease	Intervention/treatment	Phase
Cellulite; Edematous Fibrosclerotic Panniculopathy (EFP)	Drug: EN3835	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 7 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2a, Open Label Study to Assess the Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Females Using Photonumeric Scales, Magnetic Resonance Imaging and Histopathology
• Actual Study Start Date: November 20, 2019
• Actual Primary Completion Date: July 23, 2020
• Actual Study Completion Date: October 5, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Buttock & Posterolateral Thigh; EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)	Drug: EN3835; Collagenase Clostridium Histolyticum (CCH)

Outcome Measures

Primary Outcome Measures :

1. The Change From Baseline (Screening) in PR-PCSS [ Time Frame: Day 71 ]
   Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-point photonumeric scale rating cellulite severity from "0" (None) to "4" (Severe) from a patient's perspective

Secondary Outcome Measures :

1. The Change From Baseline (Screening) in CR-PCSS [ Time Frame: Day 22, Day 43 and Day 71 ]
   Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a 5-point photonumeric scale rating cellulite severity from "0" (None) to "4" (Severe) from a clinician's perspective
2. The Change From Baseline (Screening) in Hexsel Cellulite Severity Scale (CSS) [ Time Frame: Day 22, Day 43 and Day 71 ]
   Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite, each feature is evaluated on a 4-point scale from "0" (Low) to "3" (High)
3. MRI Before and After CCH Treatment [ Time Frame: Day 71 ]
   Magnetic Resonance Imaging (MRI) of cellulite before and after CCH treatment
4. Histopathology Before and After CCH Treatment [ Time Frame: Day 71 ]
   Histopathology of biopsies defined by the observation of the biopsied specimen by a trained Pathologist

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 50 Years (Adult)
• Sexes Eligible for Study: Female
• Gender Based Eligibility: Yes
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Have both buttocks or both posterolateral thighs with:

   1. A score of 3 or 4 (moderate or severe) as reported by the investigator using the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS).
   2. A Hexsel Cellulite Severity Scale (CSS) Subsection A "Number of Evident Depressions" score of >0, and Subsection B "Depth of Depressions" score of 2 )medium depth depression) or 3 (deep depressions)..
2. Have a minimum of 2 well defined and isolated cellulite dimples.
3. Be willing to apply sunscreen to the treatment area before each exposure to the sun for the duration of the study (from the Screening Visit through the Day 251/Early Termination Visit).
4. Be judged to be in good health.
5. Have a negative pregnancy test.
6. Be willing and able to cooperate with the requirements of the study.

Exclusion Criteria:

1. Is from a vulnerable population, as defined by the United States (US) Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
2. Has a history of sensitivity or allergy to collagenase or any other excipient of CCH.
3. Has systemic conditions (coagulation disorders, malignancy, keloidal scar, abnormal wound healing) that restricts study participation.
4. Has local (in areas to be treated) conditions (thrombosis, vascular disorder, active infection/inflammation, active cutaneous alteration, tattoo/mole) that restricts study participation.
5. Has skin laxity or linear undulations on the treatment region (both buttocks or both thighs) that can be effaced by lifting skin.
6. Requires anticoagulant or antiplatelet medication during the study.
7. Has used or intends to use any of the local applications/therapies/injections/procedures that restricts study participation.
8. Has used any form of artificial tanning (sprays, lotions, tanning booth, etc) within the 30 days prior to the first dose of study treatment or plans to use any form of artificial tanning during the study (through the Day 251/Early Termination Visit).
9. Has a positive HIV test and/or a positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) test at screening.
10. Has had any surgery, invasive procedure (eg, liposuction), injectable treatment (eg, KYBELLA®) or any similar treatment.
11. Has a history of keloids, hypertrophied scars, and/or other complications following biopsy.
12. Has any contraindications for MRI(implant containing metal, internal metallic object, permanent cosmetics/make-up, claustrophobia, syncope, low blood pressure, epilepsy, asthma, sickle cell disease) that restricts study participation.
13. Has received any collagenase treatments at any time prior to treatment in this study and/or has received EN3835 or CCH in a previous investigational study for cellulite.
14. Has previously received treatment with CCH in this clinical study.
15. Has received treatment with an investigational product within 30 days (or 5 half-lives, whichever is longer) of the Screening Visit.
16. Is pregnant and/or is providing breast milk or plans to become pregnant and/or to provide breast milk during the course of the study.
17. Has any other condition(s) that, in the investigator's opinion, might indicate the subject to be unsuitable for the study.

Contacts and Locations

Locations

United States, Florida

Endo Clinical Trial Site #1

Coral Gables, Florida, United States, 33146

Sponsors and Collaborators

Endo Pharmaceuticals

Investigators

• Study Director: Ashley Dayoub; Endo Pharmaceuticals

  Study Documents (Full-Text)

Documents provided by Endo Pharmaceuticals:

Study Protocol  [PDF] May 8, 2020

Statistical Analysis Plan  [PDF] February 20, 2020

More Information

• Responsible Party: Endo Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT04209530
• Other Study ID Numbers: EN3835-212
• First Posted: December 24, 2019
• Results First Posted: October 7, 2021
• Last Update Posted: October 7, 2021
• Last Verified: November 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP)

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Cellulite; Skin Manifestations